Integrating computational methods, IVIVC, and real-world evidence for bioequivalence assessment in transitional markets: A perspective

Tamim, Mohamed Khalil (2025) Integrating computational methods, IVIVC, and real-world evidence for bioequivalence assessment in transitional markets: A perspective. World Journal of Biology Pharmacy and Health Sciences, 22 (2). pp. 439-444. ISSN 2582-5542

[thumbnail of WJBPHS-2025-0512.pdf] Article PDF
WJBPHS-2025-0512.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial Share Alike.

Download ( 527kB)

Abstract

Current bioequivalence (BE) assessment methods for generic drugs face notable constraints - substantial costs, lengthy timelines, and narrow population representation. This perspective examines how integration of computational methods with In Vitro-In Vivo Correlation (IVIVC) and Real-World Evidence (RWE) might address these challenges, particularly for transitional regulatory environments. Markets enforcing BE requirements during marketing authorization renewals for products with years of clinical use but without formal BE studies, represent a unique case where this approach proves especially relevant. Rather than advocating replacement of traditional assessment, we suggest this tripartite framework as complementary methodology to potentially minimize unnecessary testing while maintaining scientific validity. Applications across Biopharmaceutics Classification System classes appear variable; implementation would logically follow a graduated pathway. We acknowledge current limitations while identifying specific research priorities to advance this approach.

Item Type: Article
Official URL: https://doi.org/10.30574/wjbphs.2025.22.2.0512
Uncontrolled Keywords: Bioequivalence; Computational Methods; IVIVC; Real-World Evidence; Generic Drugs; Regulatory Science
Depositing User: Editor WJBPHS
Date Deposited: 20 Aug 2025 12:02
Related URLs:
URI: https://eprint.scholarsrepository.com/id/eprint/3786